Customize your JAMA Network experience by selecting one or more topics from the list below.
Errors in Text and Figure Legend. In the Observation titled “Effect of a Single-Cycle Alternative Dosing Regimen for Rituximab for Recalcitrant Pemphigus: A Case Series of 9 Patients” by Matsukura et al, published in the June issue of the Archives (2012;148:734-739), errors occurred in the text and in the legend to Figure 1. On page 734, in the “Background” portion of the Abstract, the first sentence should have appeared as follows: “There is increasing evidence that a single cycle of rituximab (375 mg per square meter of body surface area once weekly for 4 weeks) is efficacious in patients with severe pemphigus.” On the same page, the third sentence of the main text's second paragraph should have read: “In published studies of pemphigus, the dosing schedule for rituximab is similar to that indicated for non-Hodgkin B-cell lymphoma, namely, 1 cycle of 4 weekly infusions of rituximab at a dose of 375 mg per square meter of body surface area (BSA).” In addition, on page 738, the second sentence of the “Comment” section should have read: “In previously published reports, rituximab was administered intravenously at a dosage of 375 mg per square meter of BSA once weekly for 4 infusions per course.6-8” Finally, on page 736, the second sentence of the legend to Figure 1 should have read: “A significant decrease (P < .05) was observed in the mean score (red curve) of 9 patients at 3 and 6 months compared with the mean score at baseline.”
Errors in Text and Figure Legend in: Effect of a Single-Cycle Alternative Dosing Regimen for Rituximab for Recalcitrant Pemphigus. Arch Dermatol. 2012;148(9):1012. doi:10.1001/2013.jamadermatol.279
Coronavirus Resource Center
Create a personal account or sign in to: